Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ

Luigi Varesio, Elisabetta Blasi, Gary B. Thurman, Robert H. Wiltrout, Ronald B. Herberman, James E Talmadge

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

The ability of recombinant interferon-γ (IFN-γ ) to activate mouse macrophages was investigated. The use of recombinant IFN-γ has the advantage of being devoid of contaminating lymphokines. Two preparations of IFN-7 were utilized, one which was not glycosylated and which was highly purified from Escherichia coli and another which was glycosylated and which was from transfected COS-7 monkey cells. Both preparations of recombinant IFN-γ activated murine macrophages to kill lymphoma and melanoma tumor targets, suggesting that glycosylate of the protein or the presence of other mammalian proteins is not essential for activation. Significant levels of cytolytic activity were induced from IFN-γ (1 to 10 units/ml). This activity was undiminished by treatment of the IFN-γ preparations with poly-mixin B at doses which neutralized endotoxin (50 μ g/ml). Similarly, IFN-γ, at low concentrations, induced an inhibition of migration by macrophages. Based on antiviral activity, IFN-γ was shown to be 100 to 1000 times more potent than was IFN-β as a macrophage-activating agent. Taken together, these results demonstrate that murine IFN-γ is a macrophage-activating factor which is effective at physiological concentrations. Of particular interest is the observation that the nonglycosylated E. coli-derived IFN-γ is active and therefore may be of value for therapeutic studies, since it can be easily produced in large amounts.

Original languageEnglish (US)
Pages (from-to)4465-4469
Number of pages5
JournalCancer Research
Volume44
Issue number10
StatePublished - Oct 1 1984

Fingerprint

Macrophage Activation
Interferons
Macrophages
Macrophage-Activating Factors
Escherichia coli
Lymphokines
COS Cells
Endotoxins
Haplorhini
Antiviral Agents
Melanoma
Lymphoma
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Varesio, L., Blasi, E., Thurman, G. B., Wiltrout, R. H., Herberman, R. B., & Talmadge, J. E. (1984). Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ. Cancer Research, 44(10), 4465-4469.

Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ. / Varesio, Luigi; Blasi, Elisabetta; Thurman, Gary B.; Wiltrout, Robert H.; Herberman, Ronald B.; Talmadge, James E.

In: Cancer Research, Vol. 44, No. 10, 01.10.1984, p. 4465-4469.

Research output: Contribution to journalArticle

Varesio, L, Blasi, E, Thurman, GB, Wiltrout, RH, Herberman, RB & Talmadge, JE 1984, 'Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ', Cancer Research, vol. 44, no. 10, pp. 4465-4469.
Varesio L, Blasi E, Thurman GB, Wiltrout RH, Herberman RB, Talmadge JE. Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ. Cancer Research. 1984 Oct 1;44(10):4465-4469.
Varesio, Luigi ; Blasi, Elisabetta ; Thurman, Gary B. ; Wiltrout, Robert H. ; Herberman, Ronald B. ; Talmadge, James E. / Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ. In: Cancer Research. 1984 ; Vol. 44, No. 10. pp. 4465-4469.
@article{ea007fcd0f31409c951d2574361c0b6c,
title = "Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ",
abstract = "The ability of recombinant interferon-γ (IFN-γ ) to activate mouse macrophages was investigated. The use of recombinant IFN-γ has the advantage of being devoid of contaminating lymphokines. Two preparations of IFN-7 were utilized, one which was not glycosylated and which was highly purified from Escherichia coli and another which was glycosylated and which was from transfected COS-7 monkey cells. Both preparations of recombinant IFN-γ activated murine macrophages to kill lymphoma and melanoma tumor targets, suggesting that glycosylate of the protein or the presence of other mammalian proteins is not essential for activation. Significant levels of cytolytic activity were induced from IFN-γ (1 to 10 units/ml). This activity was undiminished by treatment of the IFN-γ preparations with poly-mixin B at doses which neutralized endotoxin (50 μ g/ml). Similarly, IFN-γ, at low concentrations, induced an inhibition of migration by macrophages. Based on antiviral activity, IFN-γ was shown to be 100 to 1000 times more potent than was IFN-β as a macrophage-activating agent. Taken together, these results demonstrate that murine IFN-γ is a macrophage-activating factor which is effective at physiological concentrations. Of particular interest is the observation that the nonglycosylated E. coli-derived IFN-γ is active and therefore may be of value for therapeutic studies, since it can be easily produced in large amounts.",
author = "Luigi Varesio and Elisabetta Blasi and Thurman, {Gary B.} and Wiltrout, {Robert H.} and Herberman, {Ronald B.} and Talmadge, {James E}",
year = "1984",
month = "10",
day = "1",
language = "English (US)",
volume = "44",
pages = "4465--4469",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Potent Activation of Mouse Macrophages by Recombinant lnterferon-γ

AU - Varesio, Luigi

AU - Blasi, Elisabetta

AU - Thurman, Gary B.

AU - Wiltrout, Robert H.

AU - Herberman, Ronald B.

AU - Talmadge, James E

PY - 1984/10/1

Y1 - 1984/10/1

N2 - The ability of recombinant interferon-γ (IFN-γ ) to activate mouse macrophages was investigated. The use of recombinant IFN-γ has the advantage of being devoid of contaminating lymphokines. Two preparations of IFN-7 were utilized, one which was not glycosylated and which was highly purified from Escherichia coli and another which was glycosylated and which was from transfected COS-7 monkey cells. Both preparations of recombinant IFN-γ activated murine macrophages to kill lymphoma and melanoma tumor targets, suggesting that glycosylate of the protein or the presence of other mammalian proteins is not essential for activation. Significant levels of cytolytic activity were induced from IFN-γ (1 to 10 units/ml). This activity was undiminished by treatment of the IFN-γ preparations with poly-mixin B at doses which neutralized endotoxin (50 μ g/ml). Similarly, IFN-γ, at low concentrations, induced an inhibition of migration by macrophages. Based on antiviral activity, IFN-γ was shown to be 100 to 1000 times more potent than was IFN-β as a macrophage-activating agent. Taken together, these results demonstrate that murine IFN-γ is a macrophage-activating factor which is effective at physiological concentrations. Of particular interest is the observation that the nonglycosylated E. coli-derived IFN-γ is active and therefore may be of value for therapeutic studies, since it can be easily produced in large amounts.

AB - The ability of recombinant interferon-γ (IFN-γ ) to activate mouse macrophages was investigated. The use of recombinant IFN-γ has the advantage of being devoid of contaminating lymphokines. Two preparations of IFN-7 were utilized, one which was not glycosylated and which was highly purified from Escherichia coli and another which was glycosylated and which was from transfected COS-7 monkey cells. Both preparations of recombinant IFN-γ activated murine macrophages to kill lymphoma and melanoma tumor targets, suggesting that glycosylate of the protein or the presence of other mammalian proteins is not essential for activation. Significant levels of cytolytic activity were induced from IFN-γ (1 to 10 units/ml). This activity was undiminished by treatment of the IFN-γ preparations with poly-mixin B at doses which neutralized endotoxin (50 μ g/ml). Similarly, IFN-γ, at low concentrations, induced an inhibition of migration by macrophages. Based on antiviral activity, IFN-γ was shown to be 100 to 1000 times more potent than was IFN-β as a macrophage-activating agent. Taken together, these results demonstrate that murine IFN-γ is a macrophage-activating factor which is effective at physiological concentrations. Of particular interest is the observation that the nonglycosylated E. coli-derived IFN-γ is active and therefore may be of value for therapeutic studies, since it can be easily produced in large amounts.

UR - http://www.scopus.com/inward/record.url?scp=0021207692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021207692&partnerID=8YFLogxK

M3 - Article

VL - 44

SP - 4465

EP - 4469

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 10

ER -